首页> 外文期刊>Journal of Medicinal Chemistry >Structure-Activity relationships of targeted RuII(η 6- P -Cymene) anticancer complexes with flavonol-Derived ligands
【24h】

Structure-Activity relationships of targeted RuII(η 6- P -Cymene) anticancer complexes with flavonol-Derived ligands

机译:与黄酮醇衍生的配体的靶向RuII(η6-P-Cymene)抗癌复合物的构效关系

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

RuII(arene) complexes have been shown to be promising anticancer agents, capable of overcoming major drawbacks of currently used chemotherapeutics. We have synthesized Ru~(II)(η~6-arene) compounds carrying bioactive flavonol ligands with the aim to obtain multitargeted anticancer agents. To validate this concept, studies on the mode of action of the complexes were conducted which indicated that they form covalent bonds to DNA, have only minor impact on the cell cycle, but inhibit CDK2 and topoisomerase IIα in vitro. The cytotoxic activity was determined in human cancer cell lines, resulting in very low IC_(50) values as compared to other Ru~(II)(arene) complexes and showing a structure-activity relationship dependent on the substitution pattern of the flavonol ligand. Furthermore, the inhibition of cell growth correlates well with the topoisomerase inhibitory activity. Compared to the flavonol ligands, the Ru~(II)(η~6-p-cymene) complexes are more potent antiproliferative agents, which can be explained by potential multitargeted properties.
机译:RuII(芳烃)配合物已被证明是有前途的抗癌药,能够克服目前使用的化学治疗剂的主要缺点。我们合成了带有生物活性黄酮醇配体的Ru〜(II)(η〜6-芳烃)化合物,旨在获得多靶点抗癌药。为了验证该概念,对复合物的作用方式进行了研究,结果表明它们与DNA形成共价键,对细胞周期影响很小,但在体外抑制CDK2和拓扑异构酶IIα。在人癌细胞系中确定了细胞毒性活性,与其他Ru〜(II)(芳烃)配合物相比,IC_(50)值非常低,并且显示出与黄酮醇配体的取代模式有关的结构活性关系。此外,细胞生长的抑制与拓扑异构酶的抑制活性密切相关。与黄酮醇配体相比,Ru〜(II)(η〜6-对-cymene)配合物是更有效的抗增殖剂,这可以用潜在的多靶点性质来解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号